Cargando…
Current and Emerging Therapeutic Options in Adrenocortical Cancer Treatment
Adrenocortical carcinoma (ACC) is a very rare endocrine tumour, with variable prognosis, depending on tumour stage and time of diagnosis. The overall survival is five years from detection. Radical surgery is considered the therapy of choice in the first stages of ACC. However postoperative disease-f...
Autores principales: | Stigliano, Antonio, Cerquetti, Lidia, Sampaoli, Camilla, Bucci, Barbara, Toscano, Vincenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425859/ https://www.ncbi.nlm.nih.gov/pubmed/22934112 http://dx.doi.org/10.1155/2012/408131 |
Ejemplares similares
-
p53 Stabilization Induces Cell Growth Inhibition and Affects IGF2 Pathway in Response to Radiotherapy in Adrenocortical Cancer Cells
por: Sampaoli, Camilla, et al.
Publicado: (2012) -
Antineoplastic Effect of a Combined Mitotane Treatment/Ionizing Radiation in Adrenocortical Carcinoma: A Preclinical Study
por: Cerquetti, Lidia, et al.
Publicado: (2019) -
Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer
por: Cerquetti, Lidia, et al.
Publicado: (2021) -
GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo
por: Chimento, Adele, et al.
Publicado: (2015) -
Current management options for recurrent adrenocortical carcinoma
por: Glover, Anthony R, et al.
Publicado: (2013)